3D Bioprinting Market - Global Opportunity Analysis and Industry Forecast (2023-

o 3D Bioprinting Market to be Worth $5.21 Billion by 2030

Global 3D Bioprinting Market 2024-2031 Meticulous Research a leading global market research company, published a research report titled, 3D Bioprinting Market by Product (Bioprinter [Extrusion, Laser, SLA, FDM, SLS], Bioinks, Materials [Hydrogels, Cells, Biomaterials], Software, Accessories) Application (Cancer Research, Tissue Engineering, Drug Discovery) End User - Global Forecast to 2030. According to this latest publication from Meticulous Research , the 3D bioprinting market is projected to reach $5.21 billion by 2030, at a CAGR of 17.1% during the forecast period. The field of 3D bioprinting has seen remarkable technological advancements, enabling applications ranging from the creation of epidermal layers to the fabrication of tissues and organs, including liver models for studying diseases and cancer treatments. The development of functional tissues is among the many medical applications made feasible by these innovations. One significant advancement in the field of 3D bioprinting is its potential use for drug screening and clinical trials, which holds promise for reducing reliance on animal testing. The growth of this market is driven by factors such as technological advancements in 3D bioprinting, the rising geriatric population coupled with the growing burden of chronic diseases, and increasing R&D investments. Additionally, the increasing demand for organ transplantation is expected to offer significant market growth opportunities. However, the lack of skilled professionals and the high costs associated with 3D bioprinting restrain the growth of this market. Additionally, concerns regarding intellectual property rights and safety issues associated with the use of 3D bioprinted products are some of the challenges impeding the market's growth. Key Players The key players operating in the 3D bioprinting market are Organovo Holdings Inc. (U.S.), BICO Group AB (Sweden), Aspect Biosystems Ltd. (Canada), Cyfuse Biomedical K.K. (Japan), Advanced Solutions Life Sciences, LLC (U.S.), CollPlant Biotechnologies Ltd. (Israel), regenHU Ltd. (Switzerland), Poietis (France), REGEMAT 3D, SL (Spain), 3DBio Therapeutics (U.S.), and Foldink Life Science Technologies (Armenia). 3D Bioprinting Market: Future Outlook The 3D bioprinting market is segmented based on Product (Bioprinters [Inkjet-based, Extrusion-based, Stereolithography (SLA), Laser-based, Fused-deposition modeling (FDM), Selective laser sintering (SLS), and Other Technologies], Bioinks [Natural, Synthetic, Hybrid], Materials [Hydrogels, Extracellular Matrices, Living Cells, Biomaterials, Other Materials], Software, Accessories, and Consumables), Application (Cancer Research, Regenerative Medicines, Drug Discovery and Testing, Tissue Engineering, Biomaterials and cells research, Other Applications), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs)), and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets. The Page 1 of 3 Meticulous Research| sales@meticulousresearch.com

Global 3D Bioprinting Market 2024-2031 study also evaluates industry competitors and analyzes the regional and country-level markets. Based on product, the 3D bioprinting market is segmented into bioprinters, bioinks, materials, software, accessories, and consumables. In 2023, the bioprinters segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment is attributed to technological advancements in 3D bioprinting, growing demand for organ transplantation due to organ failure, and improved post-transplant outcomes. Additionally, the high adoption of inkjet-based printing in the research field and the increasing demand for higher durability of the structures contribute to the large market share of this segment. Based on application, the 3D bioprinting market is segmented into cancer research, regenerative medicines, drug discovery and testing, tissue engineering, biomaterials and cell research, and other applications. In 2023, the cancer research segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment is attributed to the increasing cancer research funding and developments in 3D bioprinting technology to create three-dimensional tissue that constructs and replicates the distinctive characteristics of cancers. This can support cancer medication screening and assist researchers in understanding cancer better. Based on end user, the 3D bioprinting market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations (CROs). In 2023, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the 3D bioprinting market. The large market share of this segment can be attributed to various technological advancements in 3D bioprinting that help pharmaceutical and biotechnology industries improve precision medicine and drug testing and increase new product launches of 3D bioprinters and bioinks. For instance, in July 2023, CD Bioparticles (U.S.) launched a new line of bioinks for 3D bioprinting. The new bioinks are biocompatible and highly adaptable, which makes them perfect for a variety of uses, such as tissue engineering, medicine delivery, and the creation and development of 3D biological models. Geographic Review This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, Belgium, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa. In 2023, North America is expected to account for the largest share of the 3D bioprinting market, followed by Europe and Asia-Pacific. Furthermore, in 2023, the U.S. is expected to be the largest market shareholder in North America. North America s major market share is Page 2 of 3 Meticulous Research| sales@meticulousresearch.com

Global 3D Bioprinting Market 2024-2031 attributed to the highly developed healthcare infrastructure and the presence of major market players such as Organovo Holdings Inc. (U.S.) and BICO Group AB (Sweden). Download @ https://www.meticulousresearch.com/download-sample- report/cp_id=5746 Sample Report Here Key questions answered in the report: Which are the high-growth market segments in terms of product, application, end user, and region/country? What was the historical market size for 3D bioprinting across the globe? What are the market forecasts and estimates for 2023 2030? What are the major drivers, restraints, and opportunities in the global 3D bioprinting market? Who are the major players in the global 3D bioprinting market? What is the competitive landscape like, and who are the market leaders in the global 3D bioprinting market? What are the recent developments in the 3D bioprinting market? What strategies are adopted by the major players in the 3D bioprinting market? What are the geographical trends and high-growth regions/countries? Contact Meticulous Email- sales@meticulousresearch.com Contact Connect with us on research Us: Research Sales- +1-646-781-8004 LinkedIn- https://www.linkedin.com/company/meticulous- Page 3 of 3 Meticulous Research| sales@meticulousresearch.com